369 related articles for article (PubMed ID: 25961889)
1. Meconium Tenofovir Concentrations and Growth and Bone Outcomes in Prenatally Tenofovir Exposed HIV-Uninfected Children.
Himes SK; Wu JW; Jacobson DL; Tassiopoulos K; Hazra R; Kacanek D; Van Dyke RB; Rich KC; Siberry GK; Huestis MA;
Pediatr Infect Dis J; 2015 Aug; 34(8):851-7. PubMed ID: 25961889
[TBL] [Abstract][Full Text] [Related]
2. Detectable HIV RNA in late pregnancy associated with low tenofovir hair levels at time of delivery among women living with HIV in the United States.
Pintye J; Huo Y; Kacanek D; Zhang K; Kuncze K; Okochi H; Gandhi M;
AIDS; 2021 Feb; 35(2):267-274. PubMed ID: 33055571
[TBL] [Abstract][Full Text] [Related]
3. Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy.
Bukkems VE; Smolders EJ; Jourdain G; Burger DM; Colbers AP; Cressey TR;
J Clin Pharmacol; 2021 Mar; 61(3):388-393. PubMed ID: 32960984
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants.
Flynn PM; Mirochnick M; Shapiro DE; Bardeguez A; Rodman J; Robbins B; Huang S; Fiscus SA; Van Rompay KK; Rooney JF; Kearney B; Mofenson LM; Watts DH; Jean-Philippe P; Heckman B; Thorpe E; Cotter A; Purswani M;
Antimicrob Agents Chemother; 2011 Dec; 55(12):5914-22. PubMed ID: 21896911
[TBL] [Abstract][Full Text] [Related]
5. Safety of tenofovir during pregnancy: early growth outcomes and hematologic side effects in HIV-exposed uninfected infants.
Seidel V; Weizsäcker K; Henrich W; Rancourt RC; Bührer C; Krüger R; Feiterna-Sperling C
Eur J Pediatr; 2020 Jan; 179(1):99-109. PubMed ID: 31659467
[TBL] [Abstract][Full Text] [Related]
6. Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy.
Siberry GK; Jacobson DL; Kalkwarf HJ; Wu JW; DiMeglio LA; Yogev R; Knapp KM; Wheeler JJ; Butler L; Hazra R; Miller TL; Seage GR; Van Dyke RB; Barr E; Davtyan M; Mofenson LM; Rich KC;
Clin Infect Dis; 2015 Sep; 61(6):996-1003. PubMed ID: 26060285
[TBL] [Abstract][Full Text] [Related]
7. Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding.
Mofenson LM; Baggaley RC; Mameletzis I
AIDS; 2017 Jan; 31(2):213-232. PubMed ID: 27831952
[TBL] [Abstract][Full Text] [Related]
8. Bone Age and Mineral Density Assessments Using Plain Roentgenograms in Tenofovir-exposed Infants in Malawi and Brazil Enrolled in HIV Prevention Trials Network 057.
Osorio LE; Boechat MI; Mirochnick M; Kumwenda N; Kreitchmann R; Emel L; Pinto J; Joao E; Santos B; Swenson M; George K; Sato P; Mofenson L; Nielsen-Saines K;
Pediatr Infect Dis J; 2017 Feb; 36(2):184-188. PubMed ID: 27798550
[TBL] [Abstract][Full Text] [Related]
9. In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers.
Viganò A; Mora S; Giacomet V; Stucchi S; Manfredini V; Gabiano C; Salvini F; Cellini M; Tamburrini E; Puzzovio M; Zuccotti GV
Antivir Ther; 2011; 16(8):1259-66. PubMed ID: 22155907
[TBL] [Abstract][Full Text] [Related]
10. Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial.
Stranix-Chibanda L; Tierney C; Sebikari D; Aizire J; Dadabhai S; Zanga A; Mukwasi-Kahari C; Vhembo T; Violari A; Theron G; Moodley D; George K; Fan B; Sommer MJ; Browning R; Mofenson LM; Shepherd J; Nelson B; Fowler MG; Siberry GK;
PLoS One; 2021; 16(2):e0246272. PubMed ID: 33544759
[TBL] [Abstract][Full Text] [Related]
11. A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring.
Keller MJ; Mesquita PM; Marzinke MA; Teller R; Espinoza L; Atrio JM; Lo Y; Frank B; Srinivasan S; Fredricks DN; Rabe L; Anderson PL; Hendrix CW; Kiser PF; Herold BC
AIDS; 2016 Mar; 30(5):743-51. PubMed ID: 26605514
[TBL] [Abstract][Full Text] [Related]
12. Maternal Tenofovir Disoproxil Fumarate Use in Pregnancy and Growth Outcomes among HIV-Exposed Uninfected Infants in Kenya.
Pintye J; Langat A; Singa B; Kinuthia J; Odeny B; Katana A; Nganga L; John-Stewart G; McGrath CJ
Infect Dis Obstet Gynecol; 2015; 2015():276851. PubMed ID: 26823647
[TBL] [Abstract][Full Text] [Related]
13. Meconium Atazanavir Concentrations and Early Language Outcomes in HIV-Exposed Uninfected Infants With Prenatal Atazanavir Exposure.
Himes SK; Huo Y; Siberry GK; Williams PL; Rice ML; Sirois PA; Frederick T; Hazra R; Huestis MA;
J Acquir Immune Defic Syndr; 2015 Jun; 69(2):178-86. PubMed ID: 26009830
[TBL] [Abstract][Full Text] [Related]
14. In Utero Tenofovir Exposure Is not Associated With Fetal Long Bone Growth.
Jao J; Abrams EJ; Phillips T; Petro G; Zerbe A; Myer L
Clin Infect Dis; 2016 Jun; 62(12):1604-1609. PubMed ID: 27009251
[TBL] [Abstract][Full Text] [Related]
15. Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.
Havens PL; Stephensen CB; Van Loan MD; Schuster GU; Woodhouse LR; Flynn PM; Gordon CM; Pan CG; Rutledge B; Liu N; Wilson CM; Hazra R; Hosek SG; Anderson PL; Seifert SM; Kapogiannis BG; Mulligan K;
Clin Infect Dis; 2017 Feb; 64(3):317-325. PubMed ID: 28013265
[TBL] [Abstract][Full Text] [Related]
16. Low levels of tenofovir in breast milk support breastfeeding in HBV-infected mothers treated with tenofovir disoproxil fumarate.
Li S; Jin J; Jiang Y; Shi J; Jiang X; Lin N; Ma Z
Int J Antimicrob Agents; 2023 Mar; 61(3):106726. PubMed ID: 36646229
[TBL] [Abstract][Full Text] [Related]
17. Antiretroviral Drugs in Meconium: Detection for Different Gestational Periods of Exposure.
Himes SK; Tassiopoulos K; Yogev R; Huestis MA;
J Pediatr; 2015 Aug; 167(2):305-11.e3. PubMed ID: 26001315
[TBL] [Abstract][Full Text] [Related]
18. Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis.
Koenig HC; Mounzer K; Daughtridge GW; Sloan CE; Lalley-Chareczko L; Moorthy GS; Conyngham SC; Zuppa AF; Montaner LJ; Tebas P
HIV Med; 2017 Jul; 18(6):412-418. PubMed ID: 28444867
[TBL] [Abstract][Full Text] [Related]
19. Tenofovir Disoproxil Fumarate Use during Pregnancy and Infant Bone Health: the Tenofovir in Pregnancy Pilot Study.
Kourtis AP; Wiener J; Wang L; Fan B; Shepherd JA; Chen L; Liu W; Shepard C; Wang L; Wang A; Bulterys M
Pediatr Infect Dis J; 2018 Nov; 37(11):e264-e268. PubMed ID: 30067600
[TBL] [Abstract][Full Text] [Related]
20. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.
Gafni RI; Hazra R; Reynolds JC; Maldarelli F; Tullio AN; DeCarlo E; Worrell CJ; Flaherty JF; Yale K; Kearney BP; Zeichner SL
Pediatrics; 2006 Sep; 118(3):e711-8. PubMed ID: 16923923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
